Name | Number of supported studies | Average coverage | |
---|---|---|---|
enterocyte | 5 studies | 24% ± 6% | |
hepatocyte | 4 studies | 73% ± 11% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 41% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 29686.77 | 226 / 226 | 89% | 651.56 | 362 / 406 |
adrenal gland | 100% | 21367.99 | 258 / 258 | 41% | 439.14 | 95 / 230 |
bladder | 67% | 196.33 | 14 / 21 | 19% | 10.50 | 98 / 504 |
stomach | 79% | 670.40 | 284 / 359 | 7% | 3.67 | 20 / 286 |
intestine | 29% | 171.92 | 281 / 966 | 5% | 1.86 | 28 / 527 |
peripheral blood | 30% | 69.93 | 281 / 929 | 0% | 0 | 0 / 0 |
ovary | 23% | 12.47 | 42 / 180 | 0% | 0.17 | 1 / 430 |
pancreas | 18% | 3.41 | 59 / 328 | 4% | 0.97 | 8 / 178 |
spleen | 22% | 51.02 | 52 / 241 | 0% | 0 | 0 / 0 |
lung | 18% | 4.21 | 102 / 578 | 1% | 0.56 | 10 / 1155 |
esophagus | 11% | 3.25 | 153 / 1445 | 4% | 2.45 | 7 / 183 |
uterus | 13% | 3.16 | 22 / 170 | 1% | 0.54 | 6 / 459 |
prostate | 14% | 4.49 | 34 / 245 | 0% | 0 | 0 / 502 |
thymus | 10% | 8.13 | 64 / 653 | 0% | 0.02 | 1 / 605 |
adipose | 10% | 9.41 | 118 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 8% | 2.11 | 103 / 1335 | 0% | 0 | 0 / 0 |
skin | 7% | 2.02 | 131 / 1809 | 0% | 0.21 | 2 / 472 |
kidney | 7% | 0.80 | 6 / 89 | 1% | 0.88 | 6 / 901 |
breast | 7% | 4.08 | 32 / 459 | 0% | 0.02 | 1 / 1118 |
heart | 7% | 2.17 | 59 / 861 | 0% | 0 | 0 / 0 |
brain | 6% | 1.65 | 167 / 2642 | 0% | 0 | 0 / 705 |
muscle | 5% | 0.84 | 38 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008203 | Biological process | cholesterol metabolic process |
GO_0050427 | Biological process | 3'-phosphoadenosine 5'-phosphosulfate metabolic process |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0006068 | Biological process | ethanol catabolic process |
GO_0051923 | Biological process | sulfation |
GO_0042403 | Biological process | thyroid hormone metabolic process |
GO_0008202 | Biological process | steroid metabolic process |
GO_0030573 | Biological process | bile acid catabolic process |
GO_0016042 | Biological process | lipid catabolic process |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0050656 | Molecular function | 3'-phosphoadenosine 5'-phosphosulfate binding |
GO_0050294 | Molecular function | steroid sulfotransferase activity |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0047704 | Molecular function | bile-salt sulfotransferase activity |
GO_0004027 | Molecular function | alcohol sulfotransferase activity |
Gene name | SULT2A1 |
Protein name | Sulfotransferase (EC 2.8.2.-) Sulfotransferase 2A1 (ST2A1) (EC 2.8.2.2) (Bile salt sulfotransferase) (EC 2.8.2.14) (Dehydroepiandrosterone sulfotransferase) (DHEA-ST) (DHEA-ST8) (Hydroxysteroid Sulfotransferase) (HST) (ST2) (SULT2A3) |
Synonyms | HST hCG_201431 STD |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfonation of steroids and bile acids in the liver and adrenal glands. Mediates the sulfation of a wide range of steroids and sterols, including pregnenolone, androsterone, DHEA, bile acids, cholesterol and as well many xenobiotics that contain alcohol and phenol functional groups . Sulfonation increases the water solubility of most compounds, and therefore their renal excretion, but it can also result in bioactivation to form active metabolites. Plays an important role in maintening steroid and lipid homeostasis . Plays a key role in bile acid metabolism . In addition, catalyzes the metabolic activation of potent carcinogenic polycyclic arylmethanols (By similarity). . |
Accessions | Q06520 ENST00000222002.4 A8K015 |